Anticancer agent 31
Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 2222930-72-3
- Formula: C28H21F2N5O2
- Molecular Weight:497.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Anticancer agent 31 (compound 2d) shows anticancer activity against human tumor cell lines (MGC-803, NCI-H460, T-24, HeLa, HepG2, and SMMC-7721) and displays lower cytotoxicity than 5-FU (HY-90006), Sorafenib.html" class="link-product" target="_blank">Sorafenib (HY-10201), and Cisplatin (HY-17394)[1].
Anticancer agent 31 (10, and 15 μM; 24 h) arrests cell cycle at S phase in MGC-803 cells, and induces tumor cells apoptosis[1].
Anticancer agent 31 (5, 10, and 15 μM; 24 h) reduces cell cycle regulatory protein CDK2, CDK4, cyclin A2, cyclin B1, and Apaf-1, anti-apoptotic protein Bcl-2; increases pro-apoptotic protein Bax protein level[1].
Anticancer agent 31 (5, 10 μM; 24 h) activates caspase-3 and caspase-9 by 73.6% and 65.3%, respectively; and also causes the loss of mitochondrial membrane potential (MMP) increase in JC-1 (HY-15534) detection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Normal cell line: HL-7702 and six human tumor cell lines: MGC-803, NCI-H460, T-24, HeLa, HepG2, and SMMC-7721
-
Concentration:
-
Incubation Time:
-
Result:Inhibited human tumor cell with IC50s of 9 μM (MGC-803), 12.3 μM (HeLa), 13.3 μM (NCI-H460), 30.4 μM (HepG2), 17.6 μM (SMMC-7721), 27.5 μM (T-24), respectively. Showed lowe cytotoxicity with an IC50 value of 80.9 μM, higher than the IC50s of tumor cell cells.
-
Cell Line:MGC-803
-
Concentration:0, 5, 10, 15 μM
-
Incubation Time:24 hours
-
Result:Decreased cell cycle regulatory protein (cyclin-dependent kinase (CDK)2, CDK4, cyclin A2, and cyclin B1) levels in a dose-dependent manner.
Suppressed anti-apoptotic protein Bcl-2 expression and up-regulated pro-apoptotic protein Bax level.
-
Cell Line:MGC-803
-
Concentration:0, 5, 10, 15 μM
-
Incubation Time:24 hours
-
Result:Caused MGC-803 cells arrest at S phase from 24.45% to 41.39% at 15 μM concentration.
Indicated that there was a interaction with DNA in the nucleus and affect DNA replication.
Increased the percentage of apoptotic tumor cells from 4.31% to 37.21%.
-
Cell Line:MGC-803
-
Concentration:5, 10 μM
-
Incubation Time:24 hours; JC-1 as the fluorescent probe
-
Result:Induced the loss of mitochondrial membrane potential (MMP) from 0.79% (control) to 37.4% (5 μM) and 81.4% (10 μM), respectively.
Chemical Information
-
CAS No. 2222930-72-3
-
Molecular Weight 497.50
-
Formula C28H21F2N5O2
-
SMILES
O=C(NC1=CC=CC(CNC2=NC3=CC(F)=C(C=C3N=C2)F)=C1)NC4=CC=C(C=C4)OC5=CC=CC=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)